Assessment of Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1 in Breast Cancer Tissue: Historical Aspects and Future Prospects

Documenti analoghi

• Prospective Biomarker Trials Chemo N0 and NNBC-3 Europe Validate the Clinical Utility of Invasion Markers uPA and PAI-1 in Node-Negative Breast Cancer
  di: Harbeck, Nadia, et al.
  Pubblicazione: (2008)
• Inhibition of NF-kappa B-Rel A expression by antisense oligodeoxynucleotides suppresses synthesis of urokinase-type plasminogen activator (uPA) but not its inhibitor PAI-1.
  di: Reuning, U, et al.
  Pubblicazione: (1995)
• Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas.
  di: Bouchet, C., et al.
  Pubblicazione: (1994)
• β(3)A-Integrin Downregulates the Urokinase-Type Plasminogen Activator Receptor (u-PAR) through a PEA3/ets Transcriptional Silencing Element in the u-PAR Promoter
  di: Hapke, Sandra, et al.
  Pubblicazione: (2001)
• Plasminogen activator inhibitor-1 (PAI-1) and urokinase plasminogen activator (uPA) in sputum of allergic asthma patients.
  di: Sebastian Zukowski, et al.
  Pubblicazione: (2008-06-01)